Cargando…

Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells

Women with triple negative breast cancer (TNBC) have poor prognosis compared to other breast cancer subtypes. There were several reports indicating racial disparity in breast cancer outcomes between African American (AA) and European American (EA) women. For example, the mortality rates of AA breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Shuping, Cheryan, Vino T., Xu, Liping, Rishi, Arun K., Reddy, Kaladhar B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560738/ https://www.ncbi.nlm.nih.gov/pubmed/28817737 http://dx.doi.org/10.1371/journal.pone.0183578

Ejemplares similares

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Disheveled3 enhanced EMT and cancer stem-like cells properties via Wnt/β-catenin/c-Myc/SOX2 pathway in colorectal cancer
por: Li, Zhengguang, et al.
Publicado: (2023)

Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins
por: Zheng, Chanjuan, et al.
Publicado: (2021)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

Stem Cells: Current Status and Therapeutic Implications
por: Reddy, Kaladhar B.
Publicado: (2020)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers
por: Cheriyan, Vino T., et al.
Publicado: (2016)

microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer
por: Rostas, Jack W, et al.
Publicado: (2014)

Identification of two cancer stem cell-like populations in triple-negative breast cancer xenografts
por: Nakayama, Jun, et al.
Publicado: (2022)

New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer
por: Khaled, Noura, et al.
Publicado: (2019)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

LIPH promotes metastasis by enriching stem‐like cells in triple‐negative breast cancer
por: Zhang, Yixiao, et al.
Publicado: (2020)

Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity
por: Le Minh, Giang, et al.
Publicado: (2023)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Regulation of cancer stem cells in triple negative breast cancer
por: Fultang, Norman, et al.
Publicado: (2021)

PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation
por: Gao, Xueqiang, et al.
Publicado: (2019)

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer
por: Wang, Yuyi, et al.
Publicado: (2018)

Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer
por: Sun, Huizhi, et al.
Publicado: (2019)

Cystine addiction of triple negative breast cancer associated with EMT augmented death signaling
por: Tang, Xiaohu, et al.
Publicado: (2016)

Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4
por: Ahmad, Aamir, et al.
Publicado: (2015)

Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro
por: Olsson, Maxim, et al.
Publicado: (2023)

On the connections between cancer stem cells and EMT
por: Cioce, Mario, et al.
Publicado: (2012)

Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway
por: Yang, Lihui, et al.
Publicado: (2021)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells
por: He, Huan, et al.
Publicado: (2023)

CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
por: Petruk, Nataliia, et al.
Publicado: (2021)

The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer
por: Chiang, Yi-Fen, et al.
Publicado: (2023)

CARP-1 / CCAR1: A biphasic regulator of cancer cell growth and apoptosis
por: Muthu, Magesh, et al.
Publicado: (2015)

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2019)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells
por: Rodriguez-Aznar, Eva, et al.
Publicado: (2019)

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
por: Brisard, Daphne, et al.
Publicado: (2018)

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2015)

Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP/TAZ activity
por: Li, Ying-Wei, et al.
Publicado: (2018)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT
por: Jin, Yujin, et al.
Publicado: (2019)

Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells
por: Kashyap, Akanksha, et al.
Publicado: (2021)

MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer
por: Ma, Sugang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ueggudq196tap0iq1gh3bper39